Mutations in the Gene Are a Prognostic Factor for Patients with Lung Squamous Cell Carcinomas

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2022 Jan 12

PMID 35018111

Authors

Sheng Zou

Jiayue Ye

Sheng Hu

Yiping Wei

Jianjun Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: To analyze the relationship between titin () mutation gene and tumor mutational burden (TMB) and the with prognosis of lung squamous cell carcinomas (LUSC), and to explore the feasibility of as a potential prognostic marker of for LUSC.

Methods: We analyzed the somatic mutation landscape of LUSC samples using datasets obtained from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases. Sequence data were divided into wild and mutant groups, and differences in TMB values between the groups compared using a Mann-Whitney -test. The Kaplan Meier method was used to analyze the correlation between mutation and LUSC prognosis, whereas CIBERSORT algorithm was used to calculate the degree of relative enrichment degree of among tumor-infiltrating lymphocytes in LUSC.

Results: Analysis of both datasets revealed high mutations in the gene, with mutants exhibiting a significantly higher TMB value relative to the wild-type (P < 0.001). Prognosis of the TTN mutant group in LUSC was significantly better than that of wild-type (P = 0.009). Kaplan Meier curves showed that TTN mutation may be an independent prognostic factor in LUSC patients (HR: 0.64, 95% CI 0.48-0.85, P = 0.001), while GSEA analysis revealed that TTN mutation plays a potential role in the development of LUSC. Finally, analysis of LUSC immune microenvironment revealed that mutation was significantly associated with enrichment of macrophages M1 (p < 0.05).

Conclusion: mutation is associated with TMB, and is positively correlated with prognosis of LUSC. Therefore, this mutation may serve as a potential prognostic indicator of LUSC.

Citing Articles

Tumor-Associated Macrophages: Key Players in the Non-Small Cell Lung Cancer Tumor Microenvironment.

Lv T, Fan R, Wu J, Gong H, Gao X, Liu X Cancer Med. 2025; 14(3):e70670.

PMID: 39927632 PMC: 11808749. DOI: 10.1002/cam4.70670.

Clinicopathological and molecular features of lung cancers associated with cystic airspaces: an analysis of 34 cases.

Zhou F, Liu W, Ding C, Di L, Sun G J Thorac Dis. 2025; 16(12):8309-8316.

PMID: 39831239 PMC: 11740048. DOI: 10.21037/jtd-24-1310.

Titin gene mutations enhance radiotherapy efficacy via modulation of tumour immune microenvironment in rectum adenocarcinoma.

Liu H, Liu J, Guan X, Zhao Z, Cheng P, Chen H Clin Transl Med. 2025; 15(1):e70123.

PMID: 39748197 PMC: 11695211. DOI: 10.1002/ctm2.70123.

Gender and melanoma subtype-based prognostic implications of MUC16 and TTN co-occurrent mutations in melanoma: A retrospective multi-study analysis.

Kodali N, Alomary S, Bhattaru A, Eldaboush A, Schwartz R, Lipner S Cancer Med. 2024; 13(17):e70199.

PMID: 39240165 PMC: 11378355. DOI: 10.1002/cam4.70199.

Analysis of the interlink between glucose-6-phosphate dehydrogenase (G6PD) and lung cancer through multi-omics databases.

Thakor P, Siddiqui M, Patel T Heliyon. 2024; 10(15):e35158.

PMID: 39165939 PMC: 11334843. DOI: 10.1016/j.heliyon.2024.e35158.

References

Chen H, Chong W, Wu Q, Yao Y, Mao M, Wang X . Association of Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. Front Immunol. 2019; 10:1113. PMC: 6536574. DOI: 10.3389/fimmu.2019.01113. View

Watanabe H, Atsuta N, Hirakawa A, Nakamura R, Nakatochi M, Ishigaki S . A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry. 2016; 87(8):851-8. DOI: 10.1136/jnnp-2015-311541. View

Li X, Pasche B, Zhang W, Chen K . Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer. JAMA Oncol. 2018; 4(12):1691-1698. PMC: 6440715. DOI: 10.1001/jamaoncol.2018.2805. View

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

Addeo A, Friedlaender A, Banna G, Weiss G . TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol. 2021; 163:103374. DOI: 10.1016/j.critrevonc.2021.103374. View

Islami F, Torre L, Jemal A . Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015; 4(4):327-38. PMC: 4549470. DOI: 10.3978/j.issn.2218-6751.2015.08.04. View

Ciferri A, Crumbliss A . The Assembling and Contraction Mechanisms of Striated Muscles. Front Chem. 2018; 6:570. PMC: 6284003. DOI: 10.3389/fchem.2018.00570. View

Samstein R, Lee C, Shoushtari A, Hellmann M, Shen R, Janjigian Y . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51(2):202-206. PMC: 6365097. DOI: 10.1038/s41588-018-0312-8. View

Kolb E, Buterbaugh R, Rinehart C, Ensley D, Perry G, Abdelsalam K . Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody. Vaccine. 2019; 38(2):298-308. DOI: 10.1016/j.vaccine.2019.10.015. View

10.

Tanegashima T, Togashi Y, Azuma K, Kawahara A, Ideguchi K, Sugiyama D . Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clin Cancer Res. 2019; 25(15):4808-4819. DOI: 10.1158/1078-0432.CCR-18-3991. View

11.

Hofree M, Shen J, Carter H, Gross A, Ideker T . Network-based stratification of tumor mutations. Nat Methods. 2013; 10(11):1108-15. PMC: 3866081. DOI: 10.1038/nmeth.2651. View

12.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

13.

Gommerman J, Rojas O, Fritz J . Re-thinking the functions of IgA(+) plasma cells. Gut Microbes. 2014; 5(5):652-62. PMC: 4615259. DOI: 10.4161/19490976.2014.969977. View

14.

Hu Z, Bi G, Sui Q, Bian Y, Du Y, Liang J . Analyses of multi-omics differences between patients with high and low PD1/PDL1 expression in lung squamous cell carcinoma. Int Immunopharmacol. 2020; 88:106910. DOI: 10.1016/j.intimp.2020.106910. View

15.

Reck M, Rabe K . Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):849-861. DOI: 10.1056/NEJMra1703413. View

16.

Schafer S, de Marvao A, Adami E, Fiedler L, Ng B, Khin E . Titin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet. 2016; 49(1):46-53. PMC: 5201198. DOI: 10.1038/ng.3719. View

17.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

18.

Jardim D, Goodman A, Gagliato D, Kurzrock R . The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 2020; 39(2):154-173. PMC: 7878292. DOI: 10.1016/j.ccell.2020.10.001. View

19.

Rizvi N, Hellmann M, Brahmer J, Juergens R, Borghaei H, Gettinger S . Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(25):2969-79. PMC: 5569693. DOI: 10.1200/JCO.2016.66.9861. View

20.

Ritchie D, Mileshkin L, Wall D, Bartholeyns J, Thompson M, Coverdale J . In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunol Immunother. 2006; 56(2):155-63. PMC: 11030026. DOI: 10.1007/s00262-006-0181-3. View